A D Norden

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
  2. ncbi Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
  3. ncbi Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
  4. ncbi Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
  5. ncbi An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
  6. ncbi Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
  7. ncbi Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012
  8. ncbi Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C Lu-Emerson
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney Street, SW 430, Boston, MA 02115, USA
    J Neurooncol 104:287-91. 2011

Collaborators

Detail Information

Publications8

  1. ncbi Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
    ..At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor...
  2. ncbi Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
    ..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints...
  3. ncbi Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
    ..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy...
  4. ncbi Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
    ..Further understanding of the mechanisms of resistance to anti-angiogenic therapies and better selection of patients will be crucial to improve outcomes for patients with malignant glioma...
  5. ncbi An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
    ..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies...
  6. ncbi Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  7. ncbi Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012
    ..The recommended doses for further study are oral panobinostat 30 mg three times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. A phase II clinical trial in recurrent HGG is underway...
  8. ncbi Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C Lu-Emerson
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney Street, SW 430, Boston, MA 02115, USA
    J Neurooncol 104:287-91. 2011
    ..Treatment was moderately well-tolerated, although one patient sustained a grade 4 intracerebral hemorrhage. Dasatinib in conjunction with bevacizumab does not appear to have activity in patients with recurrent, heavily pretreated GBM...